FivePrime Lands Potential $495M Deal with HGS for Cancer Drug
Thursday, March 17, 2011
Less than a week after Human Genome Sciences Inc. won FDA approval for the first new lupus therapy in almost 60 years a multi-billion-dollar blockbuster HGS has dipped into its coffers to the tune of a potential $495 million for FivePrime Therapeutics Inc.'s FP-1039 product for multiple cancers, a drug still in a small Phase I trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.